Navigation Links
Senesco Announces H1N1 Influenza Survival Test Results in Mice
Date:5/26/2009

NEW BRUNSWICK, N.J., May 26 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported results of H1N1 mouse influenza survival studies that were conducted in Dr. William Scheld's lab at the University of Virginia School of Medicine. Mice treated with an siRNA against Senesco's Factor 5A gene had a 52% survival rate as opposed to a 14% survival rate for mice that received no treatment or a control siRNA.

A total of 73 mice were infected with a lethal dose of nasally administered H1N1 mouse influenza. The treated mice (n=31 mice) were administered Senesco's siRNA against Factor 5A approximately 24 hours after infection and then every other day for 11 days. Treated mice reversed the weight loss typically seen in infected mice at around day 8 of the study, which coincides with the reduced mortality. The treated mice had other reduced indicators of disease severity as measured by blood glucose and liver enzymes.

Dr. Scheld, the Bayer-Gerald L. Mandell Professor of Internal Medicine at the University of Virginia School of Medicine and past president of the Infectious Diseases Society of America, commented, "These prototype studies have demonstrated that Factor 5A is a promising candidate for future study in several infectious diseases, including a model of lethal influenza."

Bruce Galton, Senesco's President and CEO, added, "We believe these data from Dr. Scheld further underscore Factor 5A's ability to mitigate apoptosis caused by inflammation, in this case from the H1N1 flu model. As we have previously stated, one of the attributes of Senesco's Factor 5A technology is its broad applicability. While we are currently working on our primary goal of filing an investigational new drug application with the FDA for th
'/>"/>

SOURCE Senesco Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Senesco Chooses VGXI to Produce Factor 5A Plasmid
2. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
3. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
4. Senesco Technologies Initiates Preclinical Studies for Cancer Target
5. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
6. Telik Announces Presentation at ASCO Annual Meeting
7. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. TriLink BioTechnologies, Inc. Announces Supply Agreement With Osmetech Molecular Diagnostics
10. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
11. DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 3, 2015  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... Lightlake,s partner for treating opioid overdose with intranasal ... New Drug Application (NDA) to the United States ... spray formulation of naloxone, a drug intended to ...
(Date:6/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: ... license agreement with AbbVie (NYSE: ABBV ) to ... with Halozyme,s ENHANZE ™ platform. ... will receive an initial $23 million payment, followed ... each of up to nine collaboration targets. These ...
(Date:6/3/2015)... 2015  VA North Texas Health Care System ... vBloc, a technology-based, scientifically advanced weight loss therapy.  ... called the Maestro® Rechargeable System that intermittently blocks ... involving food intake and processing between the brain ... customizable to meet the needs of a patient,s ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 2Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 3Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 2Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVie 3VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3
(Date:6/3/2015)... (PRWEB) June 03, 2015 The Canton ... transforms businesses with technology, announced today that Tim Dodge ... Mr. Dodge joins The Canton Group as ... of successful customer engagements. , Tim is a tech ... for a variety of technology companies. Before joining The ...
(Date:6/3/2015)... Seattle, WA (PRWEB) June 03, 2015 On ... for the majority of genetic drug sensitivity (pharmacogenetic) testing that ... expected to impact as many as 19 million of the ... special risk of costly and life-threatening adverse drug events.(1) Sadly, ... save Medicare millions. , Precision Medicine, the use of an ...
(Date:6/3/2015)... June 03, 2015 Horizon Blue Cross Blue ... Magazine as one of the nation’s top employers for diverse ... 6 among its national list of Best Places for Diverse ... the No. 1 Regional Company. This is the sixth ... MBA Magazine for its diverse workplace policies and programs. , ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 A group ... be honored with a Global Inspire Award at DIA’s ... the organization’s outstanding volunteers for their leadership, level of ... , The recipients of the Author(s) of ... of authors whose article has made a significant impact ...
(Date:6/3/2015)... Visual BI Solutions, a leader in ... launch of the second release of its successful ... Studio. The Design Studio EXtension suite allows customers ... into their dashboarding projects. , With the second ... adding key components for customers that are looking ...
Breaking Medicine News(10 mins):Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Authors Representing TransCelerate BioPharma Inc. to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 4Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 2Health News:Visual BI Launches Second Release for its Design Studio EXtensions (DSX) for SAP® BusinessObjects™ Design Studio 3
... Wednesday evening swayed to the tunes of catchy Bollywood ... awareness// that saw participation of over 10,000 sex workers ... a pair of black trousers, matching shirt and a ... Jalaile" to the delight of the mixed gathering of ...
... with gonorrhea is probably twice as likely to develop bladder ... results in the British Journal of Cancer, lead author David ... the statement based on case studies of around 51,000 American ... men suffering from gonorrhea. Results analyzed showed that ...
... the general public. This was revealed by a research conducted ... ,Among other reasons cited, drug overdose is said to ... ailments, homicides, suicides, cancer, and smoking. This study was conducted ... a researcher and an assistant professor at University of Colorado ...
... grown soy beans may prove to be successful in ... Tulane //University cancer researcher Matthew Burow. ,Burow ... ovarian and breast cancer tumors that are stimulated by ... growth of the tumors by interfering with the tumor’s ...
... emergency medical system in the national capital to help ... and thus reduce fatalities. ,"In collaboration with the ... system in Pune. Delhi will soon have the facility," ... of Indian Origin (AAPI), said Wednesday. ,Under this ...
... acclaimed as the "gold-standard" amongst researchers for scientific studies. ... on the other, has also questioned the worth of ... complementary and alternative medicine (CAM) practices. Majority of CAM ... cure. , ,The question arises as to whether ...
Cached Medicine News:Health News:Gere Jives To Bollywood Songs To Spread AIDS Awareness 2Health News:Indo-American Doctors to Build Emergency Medical System 2Health News:Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine? 2
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Medicine Products: